Gene Therapy Clinical Trials in the UK (2026): CRISPR, AAV, and the Future of Medicine
Gene therapy has moved from science fiction to medical reality. The UK approved its first CRISPR-based treatment in 2023, and gene therapies for blood disorders, inherited retinal diseases, and metabolic conditions are advancing through clinical trials. This guide covers what is available and how patients can access these groundbreaking treatments.
CRISPR: From Discovery to Treatment
The approval of Casgevy (exagamglogene autotemcel) by the MHRA marked a watershed moment — the first CRISPR-based medicine approved anywhere in the world. This treatment edits patients' own blood stem cells to produce functional haemoglobin, effectively curing sickle cell disease and transfusion-dependent beta-thalassaemia. UK trials continue to refine this approach, explore CRISPR for other genetic conditions, and develop next-generation gene editing tools that are even more precise.
AAV-Based Gene Therapies
Adeno-associated virus (AAV) vectors are the delivery vehicles for many gene therapies. They carry a healthy copy of a gene into cells, where it produces the missing or defective protein. UK trials are testing AAV-based therapies for haemophilia (delivering the clotting factor gene), inherited retinal diseases (restoring vision), and metabolic conditions. Challenges being addressed in trials include immune responses to the viral vector and achieving durable gene expression.
Which Conditions Are Being Targeted?
UK gene therapy trials are active across a growing range of conditions. Blood disorders (sickle cell disease, thalassaemia, haemophilia) are furthest advanced. Inherited retinal diseases like Leber congenital amaurosis and choroideremia have multiple trials. Neurological conditions including spinal muscular atrophy and Duchenne muscular dystrophy are being targeted. Metabolic disorders, immunodeficiencies, and certain cancers are also in active gene therapy trials.
How to Access Gene Therapy Trials
Gene therapy trials are typically conducted at specialist centres including UCL Great Ormond Street Institute of Child Health, Oxford University Hospitals, Cambridge University Hospitals, and King's College London. Access is usually through referral from your specialist consultant. For rare genetic conditions, patient organisations often have up-to-date information about trial availability and can provide support throughout the process.